This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Pfizer.
Reference
Osiri M, et al. Budget Impact of Sequential Treatment with Biologics, Biosimilars, and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Thai Patients with Rheumatoid Arthritis. Advances in Therapy : 11 Aug 2021. Available from: URL: https://doi.org/10.1007/s12325-021-01867-8
Rights and permissions
About this article
Cite this article
Targeted therapy starting with rituximab appears the least costly for rheumatoid arthritis. PharmacoEcon Outcomes News 885, 26 (2021). https://doi.org/10.1007/s40274-021-07968-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-07968-9